Tove Selvin
Postdoktor vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Ingrid Glimelius
- E-post:
- tove.selvin@igp.uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Publikationer
Senaste publikationer
Ingår i SLAS TECHNOLOGY, 2024
- DOI för Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
- Ladda ner fulltext (pdf) av Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
Ingår i BMC Pharmacology & Toxicology, 2024
- DOI för Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Ladda ner fulltext (pdf) av Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Ingår i BMC Cancer, 2023
- DOI för Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Ladda ner fulltext (pdf) av Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
Preclinical tumor-immune modeling: For the identification of immunomodulatory drugs
2023
Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
Ingår i Scientific Reports, 2022
- DOI för Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
- Ladda ner fulltext (pdf) av Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
Alla publikationer
Artiklar i tidskrift
Ingår i SLAS TECHNOLOGY, 2024
- DOI för Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
- Ladda ner fulltext (pdf) av Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
Ingår i BMC Pharmacology & Toxicology, 2024
- DOI för Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Ladda ner fulltext (pdf) av Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Ingår i BMC Cancer, 2023
- DOI för Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Ladda ner fulltext (pdf) av Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
Ingår i Scientific Reports, 2022
- DOI för Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
- Ladda ner fulltext (pdf) av Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
Ingår i Scientific Reports, 2022
- DOI för Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
- Ladda ner fulltext (pdf) av Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Ingår i Scientific Reports, 2020
- DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway